Clinical trials

Our biotech mindset, combined with the scale and advantages of a global pharmaceutical company, has established us as a development powerhouse in our core areas of focus. A global network of healthcare professionals help us test new treatments and ensure their efficacy and safety by conducting studies called clinical trials.

We have therapeutically-aligned teams, global expertise in regulatory affairs, patient safety and medical affairs, as well as a proven ability to bring new, life changing therapies successfully through clinical development.

The following list displays information about clinical trials sponsored by Ipsen.
Only interventional studies that are not yet recruiting, recruiting, active not recruiting or completed since 2015 will be displayed.
The study results will be available on clintrial.gov from 12 months after the end of the study.
To learn more about available studies, go on: https://clinicaltrials.gov/.
Last updated date: 08/08/2018







Efficacy and Safety of Lanreotide Autogel© 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Phase III Trial | Completed

Conditions : Acromegaly

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

PHASE I/II TRIAL | Completed

Conditions : Acromegaly

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel© 120 mg

Phase II Trial | Recruiting

Conditions : Pancreatic Tumours, Midgut Neuroendocrine Tumours

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.

Phase IV Trial | Active, not recruiting

Conditions : Prostate Cancer

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors

Phase III Trial | Recruiting

Conditions : Neuroendocrine Tumors

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Phase III Trial | Recruiting

Conditions : Endometriosis

Chronic Administration of Diosmectite (SMECTA©) in Subjects With Chronic Diarrhoea

Phase I Trial | Completed

Conditions : Chronic Functional Diarrhea of Unknown Origin

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Phase I Trial | Completed

Conditions : Hepatic Impairment

Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

Phase I Trial | Recruiting

Conditions : Renal Impairment

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Phase II Trial | Recruiting

Conditions : Gastro-Enteropancreatic Neuroendocrine Tumor

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in NETs

PHASE I/II TRIAL | Recruiting

Conditions : Neuroendocrine Tumors

Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.

PHASE I/II TRIAL | Recruiting

Conditions : Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck, Bone Cancer, Advanced Cancer, Recurrent Disease, Metastatic Tumours

Dysport© Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

Phase III Trial | Recruiting

Conditions : Urinary Incontinence, Overactive Bladder

Dysport© Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Phase III Trial | Recruiting

Conditions : Urinary Incontinence, Overactive Bladder

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

Phase II Trial | Not Yet recruiting

Conditions : Hallux Abductovalgus

Efficacy of Diosmectite (Smecta©) in the Symptomatic Treatment of Acute Diarrhoea in Adults

Phase IV Trial | Recruiting

Conditions : Acute Diarrhoea

Study to Evaluate Effects of DYSPORT© Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

Phase IV Trial | Active, not recruiting

Conditions : Spastic Hemiparesis

Efficacy, Safety and Tolerability of Eziclen©/Izinova© Versus Klean-prep© on Bowel Cleansing in Adolescents Undergoing Colonoscopy

Phase III Trial | Recruiting

Conditions : Digestive System Disease

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase I Trial | Active, not recruiting

Conditions : Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis

Study of Irinotecan Liposome Injection (ONIVYDE©) in Patients With Small Cell Lung Cancer

PHASE II/III TRIAL | Recruiting

Conditions : Small Cell Lung Cancer

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

PHASE I/II TRIAL | Recruiting

Conditions : Pancreatic Cancer

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children

Phase III Trial | Active, not recruiting

Conditions : Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Phase III Trial | Completed

Conditions : Glabellar Lines

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Phase III Trial | Completed

Conditions : Moderate to Severe Glabellar Lines

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

Phase III Trial | Completed

Conditions : Glabellar Lines